WO2001013909A3 - Compositions and methods for treating opiate intolerance - Google Patents

Compositions and methods for treating opiate intolerance Download PDF

Info

Publication number
WO2001013909A3
WO2001013909A3 PCT/US2000/023264 US0023264W WO0113909A3 WO 2001013909 A3 WO2001013909 A3 WO 2001013909A3 US 0023264 W US0023264 W US 0023264W WO 0113909 A3 WO0113909 A3 WO 0113909A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
active compound
compositions
opiate
methylnalorphine
Prior art date
Application number
PCT/US2000/023264
Other languages
French (fr)
Other versions
WO2001013909A2 (en
Inventor
Barrett R Cooper
Original Assignee
Barrett R Cooper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Barrett R Cooper filed Critical Barrett R Cooper
Priority to AU69344/00A priority Critical patent/AU6934400A/en
Priority to CA002380524A priority patent/CA2380524A1/en
Priority to EP00957776A priority patent/EP1206264A2/en
Publication of WO2001013909A2 publication Critical patent/WO2001013909A2/en
Publication of WO2001013909A3 publication Critical patent/WO2001013909A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse

Abstract

Provided are compositions comprising an opiate analgesic and an active compound containing the R isomer of N-methylnalorphine in a pharmaceutically acceptable carrier. Also provided are methods of treating opiate intolerance by administration of an active compound containing R N-methylnalorphine or a pharmaceutically acceptable salt thereof. The active compound may be administered either acutely or chronically to subjects receiving opiate treatment. Further provided are methods of inducing analgesia by administering to a subject an opiate analgesic concurrently with an active compound containing R N-methylnalorphine or a pharmaceutically acceptable salt thereof.
PCT/US2000/023264 1999-08-25 2000-08-24 Compositions and methods for treating opiate intolerance WO2001013909A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU69344/00A AU6934400A (en) 1999-08-25 2000-08-24 Compositions and methods for treating opiate intolerance
CA002380524A CA2380524A1 (en) 1999-08-25 2000-08-24 Compositions and methods for treating opiate intolerance
EP00957776A EP1206264A2 (en) 1999-08-25 2000-08-24 Compositions and methods for treating opiate intolerance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15073999P 1999-08-25 1999-08-25
US60/150,739 1999-08-25

Publications (2)

Publication Number Publication Date
WO2001013909A2 WO2001013909A2 (en) 2001-03-01
WO2001013909A3 true WO2001013909A3 (en) 2001-05-25

Family

ID=22535805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/023264 WO2001013909A2 (en) 1999-08-25 2000-08-24 Compositions and methods for treating opiate intolerance

Country Status (5)

Country Link
US (2) US6455537B1 (en)
EP (1) EP1206264A2 (en)
AU (1) AU6934400A (en)
CA (1) CA2380524A1 (en)
WO (1) WO2001013909A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
US20050011468A1 (en) * 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
CA2475305A1 (en) * 2002-02-04 2004-02-19 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20040087606A1 (en) * 2002-11-01 2004-05-06 Voorhees Marc E. Shivering suppression during cooling to lower body temperature
JP2006522819A (en) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ,インコーポレーテッド Combination therapy of constipation combined with laxatives and peripheral opioid antagonists
BRPI0409128A (en) * 2003-04-08 2006-03-28 Progenics Pharm Inc use of peripheral opioid antagonists, especially methylnaltrexone to treat irritable bowel syndrome
EP2368553B1 (en) * 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
WO2006096626A2 (en) 2005-03-07 2006-09-14 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
AR057325A1 (en) 2005-05-25 2007-11-28 Progenics Pharm Inc SYNTHESIS OF (S) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
AR057035A1 (en) 2005-05-25 2007-11-14 Progenics Pharm Inc SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
WO2008064353A2 (en) * 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
WO2008136865A2 (en) * 2006-11-22 2008-11-13 Progenics Pharmaceuticals, Inc. (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs
ES2540551T3 (en) 2007-03-29 2015-07-10 Wyeth Llc Peripheral opioid receptor antagonists and uses thereof
JP5461386B2 (en) 2007-03-29 2014-04-02 プロジェニックス ファーマシューティカルズ,インコーポレーテッド Peripheral opioid receptor antagonists and uses thereof
MX351611B (en) 2007-03-29 2017-10-20 Wyeth Llc Crystal forms of (r) -n-methylnaltrexone bromide and uses thereof.
CN101827819B (en) * 2007-08-09 2013-06-12 伦斯勒理工学院 Quaternary opioid carboxamides
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
WO2009051824A2 (en) * 2007-10-18 2009-04-23 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
EP2730578A1 (en) 2008-02-06 2014-05-14 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnal trexone
EP2421868A4 (en) * 2009-04-24 2012-08-01 Univ Brock Processes for the preparation of morphinane and morphinone compounds
US20140021864A1 (en) * 2010-09-01 2014-01-23 Wen-Yung Liao Functional control adapter for light generating device
CN104873455B (en) 2010-12-22 2023-09-12 普渡制药公司 Coated Tamper Resistant Controlled Release Dosage Forms
US9233073B2 (en) 2010-12-23 2016-01-12 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
EA201500742A1 (en) 2013-02-05 2015-12-30 Пердью Фарма Л.П. PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113632A1 (en) * 1982-12-30 1984-07-18 Sanofi S.A. Process for the preparation of halogen methylates of levallorphane, and peripheral narcotic antagonist pharmaceutical compositions containing them
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5756514A (en) * 1996-08-22 1998-05-26 Larijani; Ghassem E. Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists
WO1999022737A1 (en) * 1997-11-03 1999-05-14 Arch Development Corporation Use of methylnaltrexone and related compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3254088A (en) 1961-03-14 1966-05-31 Lewenstein Morphine derivative
US3773955A (en) 1970-08-03 1973-11-20 Bristol Myers Co Analgetic compositions
US4466968A (en) 1980-11-24 1984-08-21 Dermall, Ltd. Method for prophylaxis or treatment of emesis and nausea
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113632A1 (en) * 1982-12-30 1984-07-18 Sanofi S.A. Process for the preparation of halogen methylates of levallorphane, and peripheral narcotic antagonist pharmaceutical compositions containing them
US4719215A (en) * 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5756514A (en) * 1996-08-22 1998-05-26 Larijani; Ghassem E. Methods for treatment and prevention of drug-induced pruritus with serotonin type 3 receptor antagonists
WO1999022737A1 (en) * 1997-11-03 1999-05-14 Arch Development Corporation Use of methylnaltrexone and related compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BIANCHETTI A. ET AL: "Quaternary derivatives of narcotic antagonists: Stereochemical requirements at the chiral nitrogen for in vitro and in vivo activity.", LIFE SCIENCES, (1983) 33/SUPPL. 1 (415-418). CODEN: LIFSAK, XP000980615 *
CLARK S J ET AL: "EVALUATION OF OPIOID-INDUCED ANTINOCICEPTIVE EFFECTS IN ANESTHETIZED AND CONSCIOUS ANIMALS", BRITISH JOURNAL OF PHARMACOLOGY, vol. 95, no. 1, 1988, pages 275 - 283, XP000980392, ISSN: 0007-1188 *
FERREIRA S H ET AL: "IS METHYL NALORPHINIUM THE PROTOTYPE OF AN IDEAL PERIPHERAL ANALGESIC", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 99, no. 1, 1984, pages 23 - 30, XP000980657, ISSN: 0014-2999 *
KIANG J.G. ET AL: "Tolerance to morphine bradycardia in the rat.", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (1983) 226/1 (187-191). CODEN: JPETAB, XP000980656 *
NOTARNICOLA A. ET AL: "Relative ability of N- methyl nalorphine and N-methyl levallorphan to prevent antinociception and intestinal transit inhibition in morphine treated rats.", LIFE SCIENCES, (1983) 33/SUPPL. 1 (481-484). CODEN: LIFSAK, XP000980614 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526723B2 (en) 2008-03-21 2016-12-27 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
US9180125B2 (en) 2008-09-30 2015-11-10 Wyeth, Llc Peripheral opioid receptor antagonists and uses thereof

Also Published As

Publication number Publication date
EP1206264A2 (en) 2002-05-22
CA2380524A1 (en) 2001-03-01
US6455537B1 (en) 2002-09-24
WO2001013909A2 (en) 2001-03-01
US20030018043A1 (en) 2003-01-23
AU6934400A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
WO2001013909A3 (en) Compositions and methods for treating opiate intolerance
WO2000021515A3 (en) Intranasal codeine for the rapid suppression of cough and rapid relief of pain
WO2003080022A3 (en) Analgesics for nasal administration
EP1700601A3 (en) Use of dextromethorphan and an oxidase inhibitor for weaning patients from narcotics and anti-despressants
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CA2274074A1 (en) Novel compounds with analgesic effect
HU219332B (en) Synergetic medicaments containing trans-(+)-2-[(dimethylamino)-methyl]-1-(3-methoxiphenyl)-cyclohexanol and acetaminophen
NZ508037A (en) A stabilized antihistamine syrup containing aminopolycarboxylic acid as stabilizer
NO996310L (en) Compositions and procedures for reducing respiratory depression and concomitant side effects of mu-opioid compounds
WO2002019999A3 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
CA2428160A1 (en) Compositions for antitumor treatment containing ecteinascidin 743
WO2002070524A3 (en) N-but-3-enyl norbuprenorphine and its use as analgesic
AU2313297A (en) Transdermally administered dextromethorphan as antitussive agent
WO2000071108A3 (en) Methods for treatment of asthma using s-oxybutynin
WO2001041705A3 (en) Novel methods for the treatment and prevention of dizziness and pruritus
WO1991018606A3 (en) Orally active nonaddicting analgesics
CA2394471A1 (en) External preparation for treating pruritus
EP0906757A3 (en) Analgesic composition comprising moxonidine and an opioid analgesic agent
WO2000026185A3 (en) Omeprazole solution and method of using same
GEP20043252B (en) Use of NOS Inhibitors by New Pharmaceutical Designation for Treatment of Chronic and Acute Pains with Mammalians
WO2001043734A3 (en) Transdermal administration of phenylpropanolamine
WO2002041841A3 (en) Compositions for adhesion prevention
WO2007069033A3 (en) Pharmaceutical compositions comprising dexibuprofen, an opiate analgesic and paracetamol
WO2003095453A1 (en) Compounds against helicobacter activity
MY133596A (en) Compound and method for the treatment of pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2380524

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 69344/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2000957776

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000957776

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000957776

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP